MicroRNA-4465 (miR-4465)

MicroRNA-4465 (miR-4465) is a small, non-coding RNA molecule that post-transcriptionally regulates gene expression by binding to complementary sequences on target messenger RNAs (mRNAs), leading to mRNA degradation or translational repression[7]. It is a member of the miR-26 family and acts primarily as a tumor suppressor in multiple malignancies (including non-small cell lung cancer, renal cell carcinoma, ovarian, liver, and other cancers) by inhibiting cell proliferation, migration, and invasion[1][3]. miR-4465 suppresses oncogenes such as EZH2 and regulatory proteins including GSK-3β, and may also modulate pathways like AKT/mTOR that are crucial for cellular metabolism and autophagy[1][3]. Despite its promising role as a molecular target in cancer biology, miR-4465 has not been established as a direct clinical biomarker or therapeutic target, and further research is required to validate its utility in patient selection or efficacy monitoring[3][4][5]. Safety concerns remain largely hypothetical given the lack of clinical application, but would likely include risks common to RNA-based therapeutics such as off-target effects and delivery challenges[3][4][5].

Other names

hsa-miR-4465MIR4465

Drugs or interventions acting on miR-4465 (or mimicking its function in research models) generally do so by: Gene silencing via binding the 3’ UTR of target mRNAs, leading to degradation or inhibition of translation (especially EZH2, GSK-3β, PTEN, DNMT3B, TET3)[1][3][7]; Modulation of oncogenic or tumor suppressor pathways, autophagy, and apoptosis[3]